Tricida Inc (NASDAQ:TCDA) SVP Dawn Parsell Otto sold 15,407 shares of Tricida stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $37.04, for a total value of $570,675.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
NASDAQ TCDA opened at $35.74 on Monday. Tricida Inc has a 1-year low of $19.43 and a 1-year high of $42.80. The firm’s 50 day moving average is $36.50. The company has a quick ratio of 8.30, a current ratio of 8.30 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $1.76 billion and a P/E ratio of -7.70.
Tricida (NASDAQ:TCDA) last posted its earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). Equities analysts expect that Tricida Inc will post -3.44 EPS for the current year.
Several large investors have recently bought and sold shares of TCDA. FMR LLC boosted its stake in shares of Tricida by 9.7% during the 1st quarter. FMR LLC now owns 1,213,065 shares of the company’s stock worth $46,849,000 after buying an additional 107,500 shares during the last quarter. MetLife Investment Advisors LLC boosted its stake in shares of Tricida by 68.8% during the 1st quarter. MetLife Investment Advisors LLC now owns 8,804 shares of the company’s stock worth $340,000 after buying an additional 3,587 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in shares of Tricida by 99.0% during the 1st quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock worth $100,000 after buying an additional 1,289 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Tricida during the 1st quarter worth about $2,546,000. Finally, Federated Investors Inc. PA boosted its stake in shares of Tricida by 8.6% during the 1st quarter. Federated Investors Inc. PA now owns 443,100 shares of the company’s stock worth $17,113,000 after buying an additional 35,200 shares during the last quarter. Institutional investors own 62.89% of the company’s stock.
A number of equities research analysts have weighed in on the company. Needham & Company LLC assumed coverage on Tricida in a report on Friday, May 24th. They set a “buy” rating and a $50.00 price objective on the stock. Zacks Investment Research raised Tricida from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a report on Saturday, March 30th. Cowen reaffirmed a “buy” rating and set a $50.00 price objective on shares of Tricida in a report on Tuesday, June 25th. Empire lifted their price objective on Tricida from $37.00 to $58.00 in a report on Monday, April 1st. Finally, Goldman Sachs Group assumed coverage on Tricida in a report on Wednesday, June 26th. They set a “buy” rating and a $48.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Tricida has a consensus rating of “Buy” and an average price target of $47.00.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Featured Article: What is a capital gains distribution?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.